Dec-2021 The evidence for Pentasa 2-4g sachets or tabs based on a new meta-analysis published in CMRO
Speaker: Professor Simon Travis, Translational Gastroenterology Unit, Linacre College, Oxford, UK
Professor Simon Travis provided a deep dive of a new systemic review & meta-analysis on efficacy and safety of oral Pentasa in mild-to-moderate ulcerative colitis published in Current Medical Research and Opinion 2021. He proffered new insight derived from this study regarding relevant endpoints and comparisons vs placebo and other 5-ASAs. This paper concludes Pentasa was similarly effective to Eudragit-S (Asacol), Eudragit-L (Salofalk), and MMX mesalazine (Mezavant) at inducing remission at low (2.25-3 vs 2.4-3 g/day, respectively) and higher doses (4 vs 4.8 g/day). When including observational data, Pentasa was significantly better in maintaining remission vs both sulphasalazine and Eudragit-S mesalazine.
